ZCCHC17: A Zinc Finger CCHC Domain-Containing Protein and a Potential Drug Target

Target Name: ZCCHC17

NCBI ID: G51538

ZCCHC17

ZCCHC17: A Zinc Finger CCHC Domain-Containing Protein and a Potential Drug Target

Zinc finger proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in various cellular processes, including gene regulation, DNA replication, and cell signaling. Zinc finger domains (ZFDs) are a subfamily of ZFPs that are characterized by a conserved pattern of amino acids that includes a Zinc finger and a C-terminal domain. Zinc finger CCHC domain-containing proteins (ZCCHPs) are a specific subclass of ZFPs that contain a Zinc finger and a C-terminal domain, which is composed of a specific amino acid sequence known as the CCHC domain. ZCCHPs have been identified as potential drug targets in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. In this article, we will discuss ZCCHC17, a Zinc finger CCHC domain-containing protein that is potential drug target and its biological significance.

Structure and Function

Zinc finger CCHC domain-containing proteins (ZCCHPs) are a subclass of transmembrane proteins that contain a Zinc finger and a C-terminal domain. The Zinc finger is a small protein domain that is composed of four amino acids, and it is responsible for protein-protein interactions and for regulating various cellular processes. The CCHC domain is a specific amino acid sequence that is conserved in ZCCHPs and is responsible for protein-carboxylic acid (ACAS) binding and modulation of protein function.

ZCCHC17 is a Zinc finger CCHC domain-containing protein that was identified as a potential drug target in various diseases. It is characterized by a Zinc finger that consists of four amino acids (Arg-Glu-Asp-Glu), a C-terminal domain that is composed of Asp-Glu-Asp-Glu, and a unique N-terminal domain that is composed of Glu-Asp-Glu-Asp. The ZCCHC17 protein has a molecular weight of 11 kDa and a calculated pI of 6.5.

Expression and Localization

ZCCHC17 is expressed in various tissues and cells, including liver, muscle, brain, and pancreatic cancer cells. It is also expressed in various cell types, including immune cells,Endothelial cells, and Pericytes. ZCCHC17 is predominantly localized to the cytoplasm of the cells and is not detectable in the cell nucleus.

Drugs that can interact with ZCCHC17 and modulate its function include small molecules, such as inhibitors of tyrosine kinase, inhibitors of protein-protein interactions, and modulators of intracellular signaling pathways. These drugs can be used to treat diseases that are characterized by the over-expression or under-expression of ZCCHC17, including cancer, neurodegenerative diseases, and autoimmune diseases.

Clinical Applications

ZCCHC17 is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. ZCCHC17 has been shown to be involved in various cellular processes, including cell signaling, DNA replication, and gene regulation. It is also involved in the development and progression of various diseases, including cancer.

For example, ZCCHC17 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. ZCCHC17 has also been shown to be involved in the development

Protein Name: Zinc Finger CCHC-type Containing 17

The "ZCCHC17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZCCHC17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets